Trend: Research points to rapid growth of R&D outsourcing

A new report from Frost & Sullivan looking at Europe's drug development business says that 40 percent of the continent's R&D work will be outsourced by 2010. The trend has left pharma companies scrambling to strike up alliances with biotechnology firms, university research centers, contract research organizations, specialized niche vendors and general service providers. "Despite cost efficiency being a contributing factor to encourage outsourcing, the impact of genomics and proteomics in therapeutics has also resulted in an increasing awareness of the benefits of outsourcing," said Dr. Amarpreet Dhiman, research analyst at Frost & Sullivan.

- see this press release for more